Jason Meyenburg is Chief Executive Officer at Gemini Therapeutics. He has more than 20 years of experience in developing and commercializing therapies for patients with serious conditions.
Prior to joining Gemini, Jason served as Chief Commercial Officer at Orchard Therapeutics, a company advancing gene therapies for rare diseases, where he was responsible for building out the global commercial operations. During his tenure at Orchard, the company acquired and integrated the gene therapy portfolio from GSK and launched an IPO of $200 million in 2019.
Before Orchard, Jason was Chief Commercial Officer of Vtesse Pharmaceuticals, a company developing a therapy for the rare disease Niemann-Pick C in collaboration with the NIH, and of Sucampo Pharmaceuticals through the acquisition of Vtesse. Before Vtesse and Sucampo, Jason spent 13 years at Alexion Pharmaceuticals in roles of increasing responsibility, including Executive Director Project Management & Japan Operations, Vice President Commercial Operations Northern/Eastern Europe and Middle East/Africa based in Switzerland, and Senior Vice President, Commercial Operations, The Americas.
Jason holds an MBA from Duke University and a B.S. in biochemistry from University of Maryland, College Park.
What is Jason Patrick Meyenburg's net worth?
The estimated net worth of Jason Patrick Meyenburg is at least $829,530.00 as of May 14th, 2021. Mr. Meyenburg owns 13,000 shares of Gemini Therapeutics stock worth more than $829,530 as of December 24th. This net worth approximation does not reflect any other assets that Mr. Meyenburg may own. Additionally, Mr. Meyenburg receives a salary of $715,960.00 as CEO at Gemini Therapeutics. Learn More about Jason Patrick Meyenburg's net worth.
How old is Jason Patrick Meyenburg?
What is Jason Patrick Meyenburg's salary?
How do I contact Jason Patrick Meyenburg?
Has Jason Patrick Meyenburg been buying or selling shares of Gemini Therapeutics?
Jason Patrick Meyenburg has not been actively trading shares of Gemini Therapeutics during the last quarter. Most recently, on Friday, May 14th, Jason Patrick Meyenburg bought 13,000 shares of Gemini Therapeutics stock. The stock was acquired at an average cost of $9.46 per share, with a total value of $122,980.00. Following the completion of the transaction, the chief executive officer now directly owns 13,000 shares of the company's stock, valued at $122,980. Learn More on Jason Patrick Meyenburg's trading history.
